Business Description
UnicoCell Biomed Co Ltd
ISIN : TW0006794001
Share Class Description:
TPE:6794: Ordinary SharesTotal Employee Number:
38Description
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.13 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.67 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 38.68 | |||||
Beneish M-Score | -2.82 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.5 | |||||
3-Year EBITDA Growth Rate | 1.2 | |||||
3-Year EPS without NRI Growth Rate | 5.2 | |||||
3-Year FCF Growth Rate | 5.5 | |||||
3-Year Book Growth Rate | 19.9 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.94 | |||||
9-Day RSI | 70.6 | |||||
14-Day RSI | 65.29 | |||||
3-1 Month Momentum % | -0.24 | |||||
6-1 Month Momentum % | -2.13 | |||||
12-1 Month Momentum % | 33.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 37.98 | |||||
Quick Ratio | 37.57 | |||||
Cash Ratio | 36.28 | |||||
Days Inventory | 265.86 | |||||
Days Sales Outstanding | 25.49 | |||||
Days Payable | 35.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.5 | |||||
Shareholder Yield % | -5.63 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.04 | |||||
Operating Margin % | -432.39 | |||||
Net Margin % | -381.48 | |||||
EBITDA Margin % | -308.76 | |||||
FCF Margin % | -322.35 | |||||
OCF Margin % | -303.33 | |||||
ROE % | -15.08 | |||||
ROA % | -13.59 | |||||
ROIC % | -65.25 | |||||
3-Year ROIIC % | 368.23 | |||||
ROC (Joel Greenblatt) % | -69.01 | |||||
ROCE % | -13.77 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 171.08 | |||||
PB Ratio | 6.26 | |||||
Price-to-Tangible-Book | 6.26 | |||||
EV-to-EBIT | -41.69 | |||||
EV-to-EBITDA | -50.91 | |||||
EV-to-Revenue | 157.18 | |||||
EV-to-FCF | -47.06 | |||||
Price-to-GF-Value | 0.84 | |||||
| Price-to-Net-Current-Asset-Value | 7.68 | |||||
| Price-to-Net-Cash | 8.08 | |||||
Earnings Yield (Greenblatt) % | -2.4 | |||||
FCF Yield % | -1.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
UnicoCell Biomed Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 30.103 | ||
| EPS (TTM) (NT$) | -1.89 | ||
| Beta | 0.31 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.32 | ||
| Volatility % | 36.1 | ||
| 14-Day RSI | 65.29 | ||
| 14-Day ATR (NT$) | 2.553589 | ||
| 20-Day SMA (NT$) | 79.87 | ||
| 12-1 Month Momentum % | 33.55 | ||
| 52-Week Range (NT$) | 60.8 - 96 | ||
| Shares Outstanding (Mil) | 63.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
UnicoCell Biomed Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
UnicoCell Biomed Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
UnicoCell Biomed Co Ltd Frequently Asked Questions
What is UnicoCell Biomed Co Ltd(TPE:6794)'s stock price today?
The current price of TPE:6794 is NT$85.20. The 52 week high of TPE:6794 is NT$96.00 and 52 week low is NT$60.80.
When is next earnings date of UnicoCell Biomed Co Ltd(TPE:6794)?
The next earnings date of UnicoCell Biomed Co Ltd(TPE:6794) is .
Does UnicoCell Biomed Co Ltd(TPE:6794) pay dividends? If so, how much?
UnicoCell Biomed Co Ltd(TPE:6794) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on UnicoCell Biomed Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers